Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice

Overview

Journal Cancer Diagn Progn

Specialty Oncology

Date 2022 Apr 11

PMID 35403128

Authors

Teiji Kuzuya

Naoto Kawabe

Senju Hashimoto

Ryoji Miyahara

Takuji Nakano

Kazunori Nakaoka

Hiroyuki Tanaka

Yohei Miyachi

Arisa Mii

Yoshinao Tanahashi

Yutaro Kato

Atsushi Sugioka

Yoshiki Hirooka

Affiliations

Soon will be listed here.

Abstract

Background/aim: The aim of this study was to investigate the outcomes of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma (HCC), including those with disease refractory to lenvatinib, in clinical practice.

Patients And Methods: Of 34 patients treated with atezolizumab plus bevacizumab, a total of 23, including 16 with lenvatinib failure, were enrolled in this retrospective study. The adverse events, changes in liver function and antitumor responses at 6 weeks after starting therapy were evaluated.

Results: The incidence of grade 3 adverse events was low, at 13.0%. Albumin-bilirubin scores did not worsen at 3 and 6 weeks compared to baseline. The objective response rate and disease control rate at 6 weeks were 17.4% and 78.3% according to Response Evaluation Criteria in Solid Tumors (RECIST), and 30.4% and 78.3% according to modified RECIST, respectively.

Conclusion: Our results suggest that atezolizumab plus bevacizumab might have potential therapeutic safety and efficacy in patients with advanced HCC, including those with disease refractory to lenvatinib. Further studies are needed to confirm the outcomes of atezolizumab plus bevacizumab after lenvatinib failure.

Citing Articles

Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies.

Campani C, Pallas D, Sidali S, Giouleme O, Blaise L, Grando V JHEP Rep. 2024; 6(11):101190.

PMID: 39524204 PMC: 11550199. DOI: 10.1016/j.jhepr.2024.101190.

Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.

Yamaba S, Imai Y, Sugawara K, Uchida Y, Fuchigami A, Uchiya H PLoS One. 2024; 19(4):e0298770.

PMID: 38687817 PMC: 11060596. DOI: 10.1371/journal.pone.0298770.

Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.

Kinami T, Uchikawa S, Kawaoka T, Yamasaki S, Kosaka M, Johira Y Cancer Med. 2024; 13(5):e7025.

PMID: 38477514 PMC: 10935873. DOI: 10.1002/cam4.7025.

Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.

Suzuki H, Iwamoto H, Tanaka T, Sakaue T, Imamura Y, Masuda A Hepatol Int. 2023; 18(2):610-622.

PMID: 37864726 PMC: 11014819. DOI: 10.1007/s12072-023-10603-z.

Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma-Importance of Good Liver Function and Good Performance Status.

Kuzuya T, Kawabe N, Ariga M, Ohno E, Funasaka K, Nagasaka M Cancers (Basel). 2023; 15(11).

PMID: 37296914 PMC: 10251863. DOI: 10.3390/cancers15112952.

References

Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T . Sorafenib . Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Anticancer Res. 2020; 40(4):2283-2290. DOI: 10.21873/anticanres.14193. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Kudo M . A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer. 2020; 9(2):119-137. PMC: 7206602. DOI: 10.1159/000505189. View

Chuma M, Uojima H, Hiraoka A, Kobayashi S, Toyoda H, Tada T . Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Hepatol Res. 2020; 51(2):201-215. DOI: 10.1111/hepr.13592. View

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

Llovet J, Villanueva A, Marrero J, Schwartz M, Meyer T, Galle P . Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology. 2020; 73 Suppl 1:158-191. DOI: 10.1002/hep.31327. View

Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T . Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma. Anticancer Res. 2020; 40(4):2089-2093. DOI: 10.21873/anticanres.14167. View

Takahashi A, Moriguchi M, Seko Y, Ishikawa H, Yo T, Kimura H . Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Anticancer Res. 2019; 39(9):5149-5156. DOI: 10.21873/anticanres.13710. View

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

10.

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

11.

Terashima T, Yamashita T, Sunagozaka H, Arai K, Kawaguchi K, Kitamura K . Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy. Hepatol Res. 2018; 48(12):956-966. DOI: 10.1111/hepr.13196. View

12.

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

13.

Kudo M . Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers (Basel). 2020; 12(5). PMC: 7281246. DOI: 10.3390/cancers12051089. View

14.

Tomonari T, Sato Y, Tanaka H, Tanaka T, Taniguchi T, Sogabe M . Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma. JGH Open. 2020; 4(6):1135-1139. PMC: 7731817. DOI: 10.1002/jgh3.12408. View

15.

Hapani S, Sher A, Chu D, Wu S . Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology. 2010; 79(1-2):27-38. DOI: 10.1159/000314980. View

16.

Gordan J, Kennedy E, Abou-Alfa G, Beg M, Brower S, Gade T . Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020; 38(36):4317-4345. DOI: 10.1200/JCO.20.02672. View

17.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T . Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma. Oncology. 2019; 97(6):334-340. DOI: 10.1159/000502095. View

18.

Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves H . Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2014; 33(6):550-8. PMC: 4322258. DOI: 10.1200/JCO.2014.57.9151. View

19.

Kudo M, Finn R, Qin S, Han K, Ikeda K, Piscaglia F . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. View

20.

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View